Hydralazine, a medication primarily used for over 70 years to treat high blood pressure (hypertension) and preeclampsia (a complication of pregnancy), has recently generated significant interest in cancer research.

The potential for hydralazine as a cancer treatment is currently pre-clinical (tested in cell lines and animals) but shows very promising results, particularly for aggressive tumors.

🔬 How Hydralazine Works Against Cancer

The recent excitement stems from the discovery of hydralazine's previously unknown molecular mechanism of action, which directly impacts cancer cell survival.

1. Targeting Glioblastoma (Brain Cancer)

• The Target: Researchers at the University of Pennsylvania found that hydralazine strongly binds to and inhibits an enzyme called 2-aminoethanethiol dioxygenase (ADO).

• The Mechanism: ADO acts like a critical "oxygen sensor" for cells. Aggressive tumors, such as glioblastoma (a highly lethal form of brain cancer), grow so fast they often create low-oxygen environments (hypoxia). The ADO enzyme helps the cancer cells adapt and survive in these harsh conditions.

• The Effect: By inhibiting ADO, hydralazine essentially shuts off the tumor cell's oxygen alarm system. This forces the glioblastoma cells into a state of senescence (dormancy or "sleep mode"), where they stop dividing and growing.

2. Anti-Angiogenesis and DNA Effects

Older research also suggested hydralazine might have other anti-cancer properties:

• Anti-Angiogenic: Some studies suggest hydralazine can interfere with signals (like VEGF and bFGF) that cancer cells use to build new blood vessels (angiogenesis), which are essential for tumor growth.

• Epigenetic Modulation: Hydralazine has been explored as a DNA demethylating agent, which is a way to potentially turn "on" tumor-suppressing genes that cancer may have silenced. This mechanism has been investigated in cancers like leukemia and colorectal cancer.

⚠️ Important Context

It is crucial to understand the current status of this research:

• Status: The most recent findings regarding ADO and glioblastoma are from in vitro (cell culture) and pre-clinical studies.

• Not a Standard Treatment: Hydralazine is not currently approved or recommended as a standalone treatment for any type of cancer. It is still classified as a medication for hypertension and related conditions.

• Repurposing Drug: The high promise of hydralazine lies in the fact that it is an FDA-approved drug with decades of safety data (for blood pressure). This means if clinical trials are successful, the path to a new cancer therapy could be faster and cheaper than developing an entirely new drug.

• Toxicity/Side Effects: Even as a blood pressure drug, hydralazine has known side effects, including a lupus-like syndrome, which must be carefully considered when using it in a new context, especially for long-term cancer therapy.

The next steps for researchers involve modifying hydralazine or designing new, more potent drugs that selectively target the ADO enzyme and can effectively cross the blood-brain barrier for treating brain tumors.

No Comments

You must log on to comment.